Morgan Stanley keeps USD 1.40 target for PetMed Express stock

Published on 10/15/2026 at 19:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PetMed Express reports next earnings on November 10, 2026. PetMed Express stock costs EUR 1.09 on October 15, 2026, up 1.68 percent on Nasdaq.

Morgan Stanley maintains coverage

Morgan Stanley maintained a Sell rating and a USD 1.40 target on September 25, 2026.
PetMed Express is scheduled to report its next earnings on November 10, 2026.
PetMed Express stock costs EUR 1.09 at Lang & Schwarz on October 15, 2026 at 7:41 p.m. CEST, up 1.68 percent on Nasdaq.
PetMed Express had a market capitalization of USD 26.5 million on October 15, 2026.

PETS, US7163821066, Illustration mit AI erstellt.

Investing.com lists Morgan Stanley as maintaining a Sell rating and a USD 1.40 12-month target for PetMed Express on September 25, 2026. Against the USD 1.22 Nasdaq price on October 15, 2026, that target is 14.75 percent above the price. At Lang & Schwarz, PetMed Express was trading at EUR 1.09 on October 15, 2026 at 7:41 p.m. CEST, up 1.68 percent on Nasdaq.

Results date sets the next marker

TradingView identifies November 10, 2026 as PetMed Express's next earnings date. The appointment gives the stock a defined event horizon after the company's first quarter of fiscal 2027 produced revenue of USD 41.02 million and a net loss of USD 6.15 million, according to the company's investor-relations overview.

Price position remains weak

PetMed Express's Nasdaq price stood at USD 1.22 on October 15, 2026 at 1:43 p.m. ET. The stock's 52-week range was USD 1.20 to USD 4.10, putting the latest Nasdaq price 1.67 percent above the low and 70.24 percent below the high. Trading volume reached 35,560 shares against an average of 111,973 shares.

Valuation and business model

The company had a market capitalization of USD 26.5 million on October 15, 2026, while its quoted P/E was minus 0.89 and its dividend yield was 0.00 percent. PetMed Express sells pet medications, food, health services and related products directly to consumers through PetMeds.com and its telephone channel.

Comparison with peers

PETS (Nasdaq, USD): up 1.68 percent, P/E minus 0.89, market capitalization USD 26.5 million
Chewy (NYSE, USD): up 3.19 percent, P/E 32.55, market capitalization USD 8.6 billion
Petco Health and Wellness (Nasdaq, USD): up 1.27 percent, P/E 24.02, market capitalization USD 687.4 million

Trading levels and dates

The immediate market question is whether the Nasdaq price can hold above USD 1.20, the lower end of its 52-week range, before the November 10, 2026 results date. Morgan Stanley's USD 1.40 target provides a separate valuation marker, but the current loss-making profile keeps the target comparison dependent on the upcoming operating update.

What the next report may clarify

The company reported negative operating cash flow of USD 7.69 million in the first quarter of fiscal 2027, while cash stood at USD 13.08 million at June 30, 2026. The next report can therefore put revenue, cash use and the path toward profitability alongside the existing analyst target.

PetMed Express stock at Lang & Schwarz

For investors in Germany, the key levels are the EUR 1.09 Lang & Schwarz price, the Nasdaq move of 1.68 percent on October 15, 2026 and the USD 1.20 52-week low. The Nasdaq comparison shows PetMed Express moving less than Chewy on the same session, while its much smaller market capitalization sets the stock apart from both peers.

The further course of trading is shown by the continuously updated real-time quote of PetMed Express stock.